Trial Profile

Phase 2, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Isatuximab (Primary) ; Bortezomib; Bortezomib; Dexamethasone; Dexamethasone; Lenalidomide
Indications Multiple myeloma
Focus Therapeutic Use

31 May 2024 Status changed from active, no longer recruiting to recruiting.
05 Jan 2024 Planned End Date changed from 13 Mar 2024 to 13 Jan 2029.
05 Jan 2024 Planned primary completion date changed from 15 Dec 2023 to 15 Sep 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com